Financhill
Buy
69

ZBH Quote, Financials, Valuation and Earnings

Last price:
$106.57
Seasonality move :
5.58%
Day range:
$105.34 - $107.78
52-week range:
$101.47 - $133.90
Dividend yield:
0.9%
P/E ratio:
20.37x
P/S ratio:
2.91x
P/B ratio:
1.72x
Volume:
3.8M
Avg. volume:
1.6M
1-year change:
-10.73%
Market cap:
$21.3B
Revenue:
$7.4B
EPS (TTM):
$5.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZBH
Zimmer Biomet Holdings
$1.8B $1.74 3.89% 14.16% $124.27
GMED
Globus Medical
$604.8M $0.65 3.07% 577.27% $94.23
HAE
Haemonetics
$342.6M $1.07 5.26% 92.62% $110.80
NTRB
Nutriband
-- -- -- -- --
RMD
ResMed
$1.2B $2.04 9.72% 64.2% $206.05
SYK
Stryker
$5.4B $2.77 9.42% 29.99% $406.60
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZBH
Zimmer Biomet Holdings
$107.12 $124.27 $21.3B 20.37x $0.24 0.9% 2.91x
GMED
Globus Medical
$82.63 $94.23 $11.3B 123.33x $0.00 0% 4.57x
HAE
Haemonetics
$75.44 $110.80 $3.8B 31.30x $0.00 0% 2.85x
NTRB
Nutriband
$4.05 -- $45M -- $0.00 0% 19.85x
RMD
ResMed
$237.27 $206.05 $34.8B 31.43x $0.53 0.85% 7.28x
SYK
Stryker
$364.60 $406.60 $139B 39.08x $0.80 0.88% 6.39x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZBH
Zimmer Biomet Holdings
34.69% 0.779 30.49% 0.57x
GMED
Globus Medical
9.7% 2.476 4.5% 1.57x
HAE
Haemonetics
58.23% 0.561 30.25% 1.87x
NTRB
Nutriband
1.68% 2.279 0.28% 4.65x
RMD
ResMed
11.54% -0.864 1.89% 1.37x
SYK
Stryker
43.45% 1.032 11.46% 1.10x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZBH
Zimmer Biomet Holdings
$1.3B $316.1M 5.84% 8.63% 15.6% $368.6M
GMED
Globus Medical
$355.2M $49M 2.05% 2.27% 7.83% $161.7M
HAE
Haemonetics
$187.4M $51.7M 6.54% 13.51% 14.96% $39.4M
NTRB
Nutriband
$191K -$1.4M -65.19% -69.58% -210.38% -$1.1M
RMD
ResMed
$717.2M $387.3M 19.59% 23.76% 31.63% $305.9M
SYK
Stryker
$3.5B $1.1B 11.09% 18.78% 19.75% $1.3B

Zimmer Biomet Holdings vs. Competitors

  • Which has Higher Returns ZBH or GMED?

    Globus Medical has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 8.28%. Zimmer Biomet Holdings's return on equity of 8.63% beat Globus Medical's return on equity of 2.27%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    70.48% $1.23 $19B
    GMED
    Globus Medical
    56.77% $0.38 $4.5B
  • What do Analysts Say About ZBH or GMED?

    Zimmer Biomet Holdings has a consensus price target of $124.27, signalling upside risk potential of 16.01%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Zimmer Biomet Holdings has higher upside potential than Globus Medical, analysts believe Zimmer Biomet Holdings is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 17 1
    GMED
    Globus Medical
    5 4 0
  • Is ZBH or GMED More Risky?

    Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

  • Which is a Better Dividend Stock ZBH or GMED?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or GMED?

    Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than Globus Medical quarterly revenues of $625.7M. Zimmer Biomet Holdings's net income of $249.1M is higher than Globus Medical's net income of $51.8M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.37x while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.91x 20.37x $1.8B $249.1M
    GMED
    Globus Medical
    4.57x 123.33x $625.7M $51.8M
  • Which has Higher Returns ZBH or HAE?

    Haemonetics has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 9.79%. Zimmer Biomet Holdings's return on equity of 8.63% beat Haemonetics's return on equity of 13.51%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    70.48% $1.23 $19B
    HAE
    Haemonetics
    54.25% $0.66 $2.1B
  • What do Analysts Say About ZBH or HAE?

    Zimmer Biomet Holdings has a consensus price target of $124.27, signalling upside risk potential of 16.01%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 46.87%. Given that Haemonetics has higher upside potential than Zimmer Biomet Holdings, analysts believe Haemonetics is more attractive than Zimmer Biomet Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 17 1
    HAE
    Haemonetics
    3 2 0
  • Is ZBH or HAE More Risky?

    Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

  • Which is a Better Dividend Stock ZBH or HAE?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or HAE?

    Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than Haemonetics quarterly revenues of $345.5M. Zimmer Biomet Holdings's net income of $249.1M is higher than Haemonetics's net income of $33.8M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.37x while Haemonetics's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 2.85x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.91x 20.37x $1.8B $249.1M
    HAE
    Haemonetics
    2.85x 31.30x $345.5M $33.8M
  • Which has Higher Returns ZBH or NTRB?

    Nutriband has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of -211%. Zimmer Biomet Holdings's return on equity of 8.63% beat Nutriband's return on equity of -69.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    70.48% $1.23 $19B
    NTRB
    Nutriband
    29.58% -$0.12 $11.4M
  • What do Analysts Say About ZBH or NTRB?

    Zimmer Biomet Holdings has a consensus price target of $124.27, signalling upside risk potential of 16.01%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 344.44%. Given that Nutriband has higher upside potential than Zimmer Biomet Holdings, analysts believe Nutriband is more attractive than Zimmer Biomet Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 17 1
    NTRB
    Nutriband
    0 0 0
  • Is ZBH or NTRB More Risky?

    Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.

  • Which is a Better Dividend Stock ZBH or NTRB?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or NTRB?

    Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than Nutriband quarterly revenues of $645.8K. Zimmer Biomet Holdings's net income of $249.1M is higher than Nutriband's net income of -$1.4M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.37x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 19.85x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.91x 20.37x $1.8B $249.1M
    NTRB
    Nutriband
    19.85x -- $645.8K -$1.4M
  • Which has Higher Returns ZBH or RMD?

    ResMed has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 25.43%. Zimmer Biomet Holdings's return on equity of 8.63% beat ResMed's return on equity of 23.76%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    70.48% $1.23 $19B
    RMD
    ResMed
    58.57% $2.11 $5.9B
  • What do Analysts Say About ZBH or RMD?

    Zimmer Biomet Holdings has a consensus price target of $124.27, signalling upside risk potential of 16.01%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 6.68%. Given that Zimmer Biomet Holdings has higher upside potential than ResMed, analysts believe Zimmer Biomet Holdings is more attractive than ResMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 17 1
    RMD
    ResMed
    6 5 0
  • Is ZBH or RMD More Risky?

    Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

  • Which is a Better Dividend Stock ZBH or RMD?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. ResMed offers a yield of 0.85% to investors and pays a quarterly dividend of $0.53 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or RMD?

    Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than ResMed quarterly revenues of $1.2B. Zimmer Biomet Holdings's net income of $249.1M is lower than ResMed's net income of $311.4M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.37x while ResMed's PE ratio is 31.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 7.28x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.91x 20.37x $1.8B $249.1M
    RMD
    ResMed
    7.28x 31.43x $1.2B $311.4M
  • Which has Higher Returns ZBH or SYK?

    Stryker has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 15.18%. Zimmer Biomet Holdings's return on equity of 8.63% beat Stryker's return on equity of 18.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZBH
    Zimmer Biomet Holdings
    70.48% $1.23 $19B
    SYK
    Stryker
    64.02% $2.16 $35.6B
  • What do Analysts Say About ZBH or SYK?

    Zimmer Biomet Holdings has a consensus price target of $124.27, signalling upside risk potential of 16.01%. On the other hand Stryker has an analysts' consensus of $406.60 which suggests that it could grow by 11.52%. Given that Zimmer Biomet Holdings has higher upside potential than Stryker, analysts believe Zimmer Biomet Holdings is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZBH
    Zimmer Biomet Holdings
    6 17 1
    SYK
    Stryker
    13 9 0
  • Is ZBH or SYK More Risky?

    Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Stryker has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.217%.

  • Which is a Better Dividend Stock ZBH or SYK?

    Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Stryker offers a yield of 0.88% to investors and pays a quarterly dividend of $0.80 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Stryker pays out 35.99% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZBH or SYK?

    Zimmer Biomet Holdings quarterly revenues are $1.8B, which are smaller than Stryker quarterly revenues of $5.5B. Zimmer Biomet Holdings's net income of $249.1M is lower than Stryker's net income of $834M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.37x while Stryker's PE ratio is 39.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 6.39x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZBH
    Zimmer Biomet Holdings
    2.91x 20.37x $1.8B $249.1M
    SYK
    Stryker
    6.39x 39.08x $5.5B $834M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 1.36% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.63% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.53% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock